Observational Study of Blood Glucose Levels and Gut Microbiota in Healthy Individuals
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01892956|
Recruitment Status : Unknown
Verified July 2013 by Tel-Aviv Sourasky Medical Center.
Recruitment status was: Recruiting
First Posted : July 8, 2013
Last Update Posted : March 27, 2014
Categorization of glucose levels into 'healthy', 'pre-diabetic' or 'diabetic' is increasingly seen as artificial. Furthermore, most micro and macrovascular complications may be present already at the pre-diabetic stage.
Hyperglycemia, pre-diabetes and impaired glucose tolerance (IGT) are fully reversible, thus, maintaining normal blood sugar levels is crucial for the prevention and control of diabetes and the various other consequences of the metabolic syndrome. Only interventions that are individually tailored can achieve proper glycemic control, and the glycemic index (GI), which quantifies the glycemic response to particular foods, was developed for this purpose.
In this study the investigators will characterize the blood glucose responses and microbiota of healthy individuals, aiming to assess the influence of food intake on gut microbiota and the influence of gut microbiota on glycemic responses.
|Condition or disease|
|Nutritional and Metabolic Diseases Endocrine System Diseases Disorders of Environmental Origin|
|Study Type :||Observational|
|Estimated Enrollment :||2000 participants|
|Official Title:||Observational Study of Blood Glucose Levels and Gut Microbiota in Healthy Individuals|
|Study Start Date :||April 2013|
|Estimated Primary Completion Date :||April 2015|
|Estimated Study Completion Date :||April 2016|
- Blood glucose levels [ Time Frame: One week ]
- DNA sequencing of the gut microbiota composition [ Time Frame: Before or during the glucose testing week ]
Biospecimen Retention: Samples Without DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01892956
|Contact: Zamir Halpern, MDfirstname.lastname@example.org|
|Tel-Aviv, Israel, 64239|
|Contact: Noya Horowitz, PhD 972-3-6974297 email@example.com|
|Principal Investigator: Zamir Halpern, MD|
|Sub-Investigator: Eran Elinav, PhD|
|Sub-Investigator: Eran Segal, PhD|
|Principal Investigator:||Zamir Halpern, MD||Tel-Aviv Sourasky Medical Center|